Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Huabo Biopharm Co., Ltd.

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor

Phase 1

Recruiting

Conditions: Advanced NSCLC
Advanced Endometrial Cancer

Interventions: Drug: HB0025
Drug: Pemetrexed
Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2025-01-03

Last Posted Date: 2025-01-23

Lead Sponsor: Huabo Biopharm Co., Ltd.

Target Recruit Count: 282

Registration Number: NCT06758557

Locations: 🇨🇳
Affiliated Hospital of Hebei University / School of Clinical Medicine, Baoding, Hebei, China
🇨🇳
Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
🇨🇳
The First Affiliated Hospital of Henan University of Science & Technology, Luoyang, Henan, China

and more 11 locations

A Phase 2 Study to Explore the Efficacy and Safety of HB0017 Longer Dose Interval in Psoriasis Patients

Phase 2

Not yet recruiting

Conditions: Psoriasis (PsO)

Interventions: Biological: HB0017

First Posted Date: 2024-09-12

Last Posted Date: 2024-09-12

Lead Sponsor: Huabo Biopharm Co., Ltd.

Target Recruit Count: 200

Registration Number: NCT06592274

Locations: 🇨🇳
Shandong First Medical University Affiliated Dermatology Hospital, Jinan, Shandong, China

Study of Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis

Phase 3

Recruiting

Conditions: Psoriasis

Interventions: Biological: HB0017 Q4W
Biological: placebo
Biological: HB0017 Q8W

First Posted Date: 2024-06-27

Last Posted Date: 2024-06-27

Lead Sponsor: Huabo Biopharm Co., Ltd.

Target Recruit Count: 400

Registration Number: NCT06477237

Locations: 🇨🇳
Jiangmen Central Hospital, Jiangmen, Guangdong, China
🇨🇳
Nanyang First People's Hospital, Nanyang, Henan, China
🇨🇳
Beijing Friendship Hospital, Beijing, China

and more 41 locations

A Study of HB0025 Injection in Patients With Advanced Renal Cancer

Phase 2

Recruiting

Conditions: Renal Cancer

Interventions: Drug: HB0025

First Posted Date: 2024-01-24

Last Posted Date: 2024-01-24

Lead Sponsor: Huabo Biopharm Co., Ltd.

Target Recruit Count: 100

Registration Number: NCT06222125

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

A Study of HB0030 Injection in Patients With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumor

Interventions: Drug: HB0030 injection

First Posted Date: 2023-01-31

Last Posted Date: 2023-01-31

Lead Sponsor: Huabo Biopharm Co., Ltd.

Target Recruit Count: 36

Registration Number: NCT05706207

Locations: 🇨🇳
the First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China

A Study to Evaluate the Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis

Phase 2

Completed

Conditions: Plaque Psoriasis

Interventions: Drug: HB0017
Other: Placebo

First Posted Date: 2022-09-08

Last Posted Date: 2024-06-21

Lead Sponsor: Huabo Biopharm Co., Ltd.

Target Recruit Count: 160

Registration Number: NCT05531682

Locations: 🇨🇳
The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
🇨🇳
The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳
The Second Hospital of Anhui Medical University, Hefei, Anhui, China

and more 18 locations

A Study of HB0017 in Patients With Moderate to Severe Plaque Psoriasis

Phase 1

Completed

Conditions: Plaque Psoriasis

Interventions: Biological: HB0017 300mg or matching placebo
Biological: HB0017 450mg or matching placebo
Biological: HB0017 150mg or matching placebo

First Posted Date: 2022-07-05

Last Posted Date: 2022-07-07

Lead Sponsor: Huabo Biopharm Co., Ltd.

Target Recruit Count: 30

Registration Number: NCT05442788

Locations: 🇨🇳
The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China

A Study of of HOT1030 in Patients With Advanced Solid Tumors

Phase 1

Conditions: Solid Tumor, Adult

Interventions: Drug: HOT-1030

First Posted Date: 2021-09-29

Last Posted Date: 2021-09-29

Lead Sponsor: Huabo Biopharm Co., Ltd.

Target Recruit Count: 42

Registration Number: NCT05060263

Locations: 🇨🇳
Shanghai Huaota Biopharmaceutical Co., Ltd., Shanghai, Shanghai, China

A Study of HB002.1T Plus Chemotherapy in Subjects With Solid Tumor

Phase 1

Conditions: Solid Tumor

Interventions: Drug: HB002.1T
Drug: Oxaliplatin
Drug: Paclitaxel
Drug: Gemcitabine
Drug: Capecitabine
Drug: Carboplatin
Drug: Cisplatin

First Posted Date: 2021-03-17

Last Posted Date: 2021-07-28

Lead Sponsor: Huabo Biopharm Co., Ltd.

Target Recruit Count: 72

Registration Number: NCT04802980

Locations: 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China

A Study of Injection HB0025 in Patients With Advanced Solid Tumors

Phase 1

Conditions: Tumor, Subjects

Interventions: Drug: HB0025

First Posted Date: 2020-12-22

Last Posted Date: 2022-06-01

Lead Sponsor: Huabo Biopharm Co., Ltd.

Target Recruit Count: 154

Registration Number: NCT04678908

Locations: 🇺🇸
NEXT Oncology, San Antonio, Texas, United States
🇨🇳
The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
🇨🇳
Central Hospital Affiliated to ShanDong First Medical University, Jinan, Shandong, China

and more 3 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy